Cardiac function in mice lacking the glucagon-like peptide-1 receptor.

Glucagon-like peptide-1 (GLP-1) acts via its G protein-coupled receptor (GLP-1R) to regulate blood glucose. Although the GLP-1R is widely expressed in peripheral tissues, including the heart, and exogenous GLP-1 administration increases heart rate and blood pressure in rodents, the physiological importance of GLP-1R action in the cardiovascular system remains unclear. We now show that 2-month-old mice with genetic deletion of the GLP-1R (GLP-1R(-/-)) exhibit reduced resting heart rate and elevated left ventricular (LV) end diastolic pressure compared with CD-1 wild-type controls. At the age of 5 months, echocardiography and histology demonstrate increased LV thickness in GLP-1R(-/-) mice. Although baseline hemodynamic parameters of GLP-1R(-/-) did not differ significantly from those of wild type, GLP-1R(-/-) mice displayed impaired LV contractility and diastolic function after insulin administration. The defective cardiovascular response to insulin was not attributable to a generalized defect in the stress response, because GLP-1R(-/-) mice responded appropriately to insulin with increased c-fos expression in the hypothalamus and increased circulating levels of glucagon and epinephrine. Furthermore, LV contractility after exogenous epinephrine infusion was also reduced in GLP-1R(-/-) mice. These findings provide new evidence implicating an essential role for GLP-1R in the control of murine cardiac structure and function in vivo.

[1]  Wallace C. Wu,et al.  Glucagon effects on the human small intestine , 1979, Digestive Diseases and Sciences.

[2]  D. Drucker,et al.  International Union of Pharmacology. XXXV. The Glucagon Receptor Family , 2003, Pharmacological Reviews.

[3]  D. Drucker Glucagon-like peptides: regulators of cell proliferation, differentiation, and apoptosis. , 2003, Molecular endocrinology.

[4]  C. Saper,et al.  Glucagon-like peptide-1 receptor stimulation increases blood pressure and heart rate and activates autonomic regulatory neurons. , 2002, The Journal of clinical investigation.

[5]  B. Janssen,et al.  Autonomic control of blood pressure in mice: basic physiology and effects of genetic modification. , 2002, American journal of physiology. Regulatory, integrative and comparative physiology.

[6]  D. Stewart,et al.  Cardiomyocyte overexpression of iNOS in mice results in peroxynitrite generation, heart block, and sudden death. , 2002, The Journal of clinical investigation.

[7]  J. Holst,et al.  Effect of 6-week course of glucagon-like peptide 1 on glycaemic control, insulin sensitivity, and β-cell function in type 2 diabetes: a parallel-group study , 2002, The Lancet.

[8]  B. Janssen,et al.  Chronic measurement of cardiac output in conscious mice. , 2002, American journal of physiology. Regulatory, integrative and comparative physiology.

[9]  D. Drucker Biological actions and therapeutic potential of the glucagon-like peptides. , 2002, Gastroenterology.

[10]  J. Stock,et al.  Glycemic control in mice with targeted disruption of the glucagon receptor gene. , 2002, Biochemical and biophysical research communications.

[11]  T. Welte,et al.  Vasorelaxant effect of glucagon-like peptide-(7-36)amide and amylin on the pulmonary circulation of the rat , 2001, Regulatory Peptides.

[12]  M. Bjerknes,et al.  Modulation of specific intestinal epithelial progenitors by enteric neurons , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[13]  A. Astrup,et al.  A meta-analysis of the effect of glucagon-like peptide-1 (7-36) amide on ad libitum energy intake in humans. , 2001, The Journal of clinical endocrinology and metabolism.

[14]  S. Sollott,et al.  Glucagon-Like Peptide-1 Increases cAMP but Fails to Augment Contraction in Adult Rat Cardiac Myocytes , 2001, Circulation research.

[15]  D. Drucker Development of glucagon-like peptide-1-based pharmaceuticals as therapeutic agents for the treatment of diabetes. , 2001, Current pharmaceutical design.

[16]  D. Drucker,et al.  Minireview: the glucagon-like peptides. , 2001, Endocrinology.

[17]  G L Freeman,et al.  Validation of a mouse conductance system to determine LV volume: comparison to echocardiography and crystals. , 2000, American journal of physiology. Heart and circulatory physiology.

[18]  B. Yusta,et al.  Enteroendocrine localization of GLP-2 receptor expression in humans and rodents. , 2000, Gastroenterology.

[19]  C. Saper,et al.  Chemical characterization of leptin‐activated neurons in the rat brain , 2000, The Journal of comparative neurology.

[20]  S. Woods,et al.  The Role of CNS Glucagon-Like Peptide-1 (7-36) Amide Receptors in Mediating the Visceral Illness Effects of Lithium Chloride , 2000, The Journal of Neuroscience.

[21]  D. Drucker,et al.  The Glucagon Receptor Family , 2000 .

[22]  J. Habener,et al.  The glucagon-like peptides. , 1999, Endocrine reviews.

[23]  E. Blázquez,et al.  Neural contribution to the effect of glucagon-like peptide-1-(7-36) amide on arterial blood pressure in rats. , 1999, American journal of physiology. Endocrinology and metabolism.

[24]  G. V. Dijk,et al.  Glucagon-like peptide-1 (7–36) amide: a central regulator of satiety and interoceptive stress , 1999, Neuropeptides.

[25]  J. Holst Glucagon-like Peptide 1 (GLP-1): An Intestinal Hormone, Signalling Nutritional Abundance, with an Unusual Therapeutic Potential , 1999, Trends in Endocrinology & Metabolism.

[26]  L. Rinaman Interoceptive stress activates glucagon-like peptide-1 neurons that project to the hypothalamus. , 1999, The American journal of physiology.

[27]  J. Holst,et al.  Continuous subcutaneous infusion of glucagon-like peptide 1 lowers plasma glucose and reduces appetite in type 2 diabetic patients. , 1999, Diabetes care.

[28]  D. Drucker Glucagon-like Peptide 2 , 1999, Trends in Endocrinology & Metabolism.

[29]  C. M. White A Review of Potential Cardiovascular Uses of Intravenous Glucagon Administration , 1999, Journal of clinical pharmacology.

[30]  D. Drucker,et al.  Prototypic G protein-coupled receptor for the intestinotrophic factor glucagon-like peptide 2. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[31]  P. Shughrue,et al.  Distribution of pre‐pro‐glucagon and glucagon‐like peptide‐1 receptor messenger RNAs in the rat central nervous system , 1999, The Journal of comparative neurology.

[32]  J. Holst,et al.  Inhibitory effect of glucagon-like peptide-1 on small bowel motility. Fasting but not fed motility inhibited via nitric oxide independently of insulin and somatostatin. , 1998, The Journal of clinical investigation.

[33]  J. Howell,et al.  A potential role for glucagon in the treatment of drug-induced symptomatic bradycardia. , 1998, Chest.

[34]  D. Drucker,et al.  Effects of Aging and a High Fat Diet on Body Weight and Glucose Tolerance in Glucagon-Like Peptide-1 Receptor-/- Mice. , 1998, Endocrinology.

[35]  J. Dunphy,et al.  Tissue distribution of rat glucagon receptor and GLP-1 receptor gene expression 1 This work was supported by a grant from the Crohn's and Colitis Foundation of America. 1 , 1998, Molecular and Cellular Endocrinology.

[36]  D. Drucker,et al.  Effects of aging and a high fat diet on body weight and glucose tolerance in glucagon-like peptide-1 receptor -/- mice. , 1998, Endocrinology.

[37]  George Paxinos,et al.  The Mouse Brain in Stereotaxic Coordinates , 2001 .

[38]  S. Bloom,et al.  Cardiovascular and pancreatic endocrine responses to glucagon‐like peptide‐1(7–36) amide in the conscious calf , 1997, Experimental physiology.

[39]  B. Göke,et al.  Differential effects of subcutaneous GLP-1 on gastric emptying, antroduodenal motility, and pancreatic function in men. , 1997, Proceedings of the Association of American Physicians.

[40]  E. Blázquez,et al.  Interactions of exendin-(9–39) with the effects of glucagon-like peptide-1-(7–36) amide and of exendin-4 on arterial blood pressure and heart rate in rats , 1996, Regulatory Peptides.

[41]  A. Joyner,et al.  Glucose intolerance but normal satiety in mice with a null mutation in the glucagon–like peptide 1 receptor gene , 1996, Nature Medicine.

[42]  D. Drucker,et al.  Induction of intestinal epithelial proliferation by glucagon-like peptide 2. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[43]  J. Habener,et al.  Tissue distribution of messenger ribonucleic acid encoding the rat glucagon-like peptide-1 receptor. , 1996, Endocrinology.

[44]  B. Thorens,et al.  Expression of the Glucagon‐Like Peptide‐1 Receptor Gene in Rat Brain , 1996, Journal of neurochemistry.

[45]  D. Smith,et al.  A role for glucagon-like peptide-1 in the central regulation of feeding , 1996, Nature.

[46]  F. Pecker,et al.  Synergistic actions of glucagon and miniglucagon on Ca2+ mobilization in cardiac cells. , 1996, Circulation research.

[47]  S. Mojsov,et al.  Tissue‐specific expression of the human receptor for glucagon‐like peptide‐I: brain, heart and pancreatic forms have the same deduced amino acid sequences , 1995, FEBS letters.

[48]  P. Robberecht,et al.  Relative quantitative analysis of glucagon receptor mRNA in rat tissues , 1994, Molecular and Cellular Endocrinology.

[49]  D. Drucker,et al.  Divergent tissue-specific and developmental expression of receptors for glucagon and glucagon-like peptide-1 in the mouse. , 1994, Endocrinology.

[50]  E. Blázquez,et al.  Changes in arterial blood pressure and heart rate induced by glucagon-like peptide-1-(7-36) amide in rats. , 1994, The American journal of physiology.

[51]  C. Strader,et al.  Cloning and expression of a human glucagon receptor. , 1994, Biochemical and biophysical research communications.

[52]  B. Göke,et al.  GLP-1 stimulates secretion of macromolecules from airways and relaxes pulmonary artery. , 1993, The American journal of physiology.

[53]  H. Eiskjær,et al.  Effect of intravenous glucagon infusion on renal haemodynamics and renal tubular handling of sodium in healthy humans , 1993 .

[54]  H. Orskov,et al.  Effect of intravenous glucagon infusion on renal haemodynamics and renal tubular handling of sodium in healthy humans. , 1993, Scandinavian journal of clinical and laboratory investigation.

[55]  B. Thorens Expression cloning of the pancreatic beta cell receptor for the gluco-incretin hormone glucagon-like peptide 1. , 1992, Proceedings of the National Academy of Sciences of the United States of America.

[56]  L. Bankir,et al.  Effects of glucagon on glomerular filtration rate and urea and water excretion. , 1992, The American journal of physiology.

[57]  R. Fischmeister,et al.  Glucagon stimulates the cardiac Ca2+ current by activation of adenylyl cyclase and inhibition of phosphodiesterase , 1990, Nature.

[58]  H. Drexler,et al.  Vasodilatory action of endogenous atrial natriuretic factor in a rat model of chronic heart failure as determined by monoclonal ANF antibody. , 1990, Circulation research.

[59]  N. Reichek,et al.  Recommendations for quantitation of the left ventricle by two-dimensional echocardiography. American Society of Echocardiography Committee on Standards, Subcommittee on Quantitation of Two-Dimensional Echocardiograms. , 1989, Journal of the American Society of Echocardiography : official publication of the American Society of Echocardiography.

[60]  Y. Oomura,et al.  Effect of intracerebroventricularly infused glucagon on feeding behavior , 1984, Physiology & Behavior.

[61]  A. Farah Glucagon and the circulation. , 1983, Pharmacological reviews.

[62]  N. Fortuin,et al.  The evaluation of left ventricular function by echocardiography. , 1977, The American journal of medicine.

[63]  W. Parmley,et al.  Cardiovascular effects of glucagon in man. , 1968, The New England journal of medicine.

[64]  H. Necheles,et al.  Effect of glucagon on gastrointestinal motility. , 1966, The American journal of gastroenterology.

[65]  S. Nef,et al.  microRNAs in the testis: building up male fertility. , 2010, Journal of andrology.